
    
      This study will be a randomized (the study medication is assigned by chance), double-blind
      (neither physician nor participant knows the identity of the assigned treatment),
      active-controlled (one of the treatments is an established effective treatment for type 2
      diabetes mellitus), parallel-group (each group of participants will be treated at the same
      time), 5-arm (groups), multicenter study. Approximately 1,200 participants will be randomly
      assigned to the 5 treatment arms in a 1:1:1:1:1 ratio for 26 weeks.
    
  